Safety of systemic treatments for Behçet’s syndrome

Giuseppe Lopalco, Donato Rigante, Antonio Lopalco, Giacomo Emmi, Vincenzo Venerito, Antonio Vitale, Giovanna Capozio, Nunzio Denora, Luca Cantarini, Florenzo Iannone

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Introduction: Treatment of Behçet’s syndrome (BS) is aimed at controlling all symptoms of such a complex disorder, ensuring a good quality of life and preventing life-threatening complications. A better understanding of the pathogenic role of different chemokines has improved our knowledge of BS and elicited a more specific use of therapies currently available, minimizing the burden of potential side-effects related to treatment. Areas covered: This work aims to provide a detailed overview of the safety profile for current therapies available in the treatment of BS, focusing on the main side-effects, toxicity and contraindications. Expert opinion: The greatest experience in the management of BS has been achieved with the employment of monoclonal anti-tumor necrosis factor antibodies which have been advocated for BS refractory manifestations. Moreover, interleukin-1 inhibitors have proven to be effective as well as safe, despite escalation of their dosage, especially to manage the most severe and difficult-to-treat ocular manifestations. However, general treatment of BS patients remains awkward as protean clinical features may respond differently to the same treatment or even worsen. Therefore, patients’ safety for therapies used in BS promotes the implementation of precision medicine, which could help targeting accurately the pathogenetic mechanisms concealed behind specific clinical phenotypes
Lingua originaleEnglish
pagine (da-a)1269-1301
Numero di pagine33
RivistaExpert Opinion on Drug Safety
Stato di pubblicazionePubblicato - 2020


  • Behçet's disease


Entra nei temi di ricerca di 'Safety of systemic treatments for Behçet’s syndrome'. Insieme formano una fingerprint unica.

Cita questo